OverviewSuggest Edit

NovellusDx is dedicated to delivering the actionable intelligence that oncologists require to choose the right therapy for each patient. NovellusDx provides comprehensive, fully-automated, functional gene profiling of individual patient tumors including charting the full landscape of known and unknown mutations that drive the cancer’s progression.

By measuring the activity of signaling pathways, NovellusDx’s Funtional Annotation for Cancer Treatment, the FACT system, assess the activity of mutations and combination of mutations and their response to targeted drugs. In addition, the FACT system support biopharma companies throughout the entire life cycle of the drug.

... Show more
TypePrivate
Founded2012
HQJerusalem, IL
Websitenovellusdx.com

Latest Updates

Key People/Management at NovellusDx

Haim Gil-Ad

Haim Gil-Ad

Co-Founder & CEO
Michael Vidne

Michael Vidne

Chief Commercial Officer
Gabi Tarcic

Gabi Tarcic

Vp R&d
Yaron Shimon

Yaron Shimon

Controller
Zohar Barbash

Zohar Barbash

Director, Assay Development
Ori Zelichov

Ori Zelichov

Director of Medical Affairs
Show more

NovellusDx Office Locations

NovellusDx has an office in Jerusalem
Show all (1)
Report incorrect company information

NovellusDx Financials and Metrics

Summary Metrics

Founding Date

2012

NovellusDx total Funding

$34.5 m

NovellusDx latest funding size

$6 m

Time since last funding

10 months ago

NovellusDx investors

NovellusDx's latest funding round in April 2018 was reported to be $6 m. In total, NovellusDx has raised $34.5 m
View all funding rounds
Report incorrect company information

NovellusDx Online and Social Media Presence

Embed Graph
Report incorrect company information

NovellusDx News and Updates

Cancer Genetics and NovellusDx Sign Definitive Agreement to Merge

Transaction to Create a Leader in Precision Oncology Transaction to Create a Leader in Precision Oncology
Report incorrect company information

NovellusDx Blogs

Why geneticists stole cancer research even though cancer is primarily a signaling disease.

In a focus article recently published in Science Signaling (Sci. Signal.  22 Jan 2019), Michael Yaffe asks "Why geneticists stole cancer research even though cancer is primarily a signaling disease." The post Why geneticists stole cancer research even though cancer is primarily a signaling disease. …

NovellusDx presenting a groundbreaking AI framework for VUS determination

NovellusDx team will be attending the AACR 2019 annual meeting and will present a poster titled: “Accurate prediction of the signaling pathway activity elicited by Variants of Uncertain Significance (VUS) and their drug sensitivity using Deep Convolutional Neural Networks on fluorescent microscopy i…

The EU Patent Office grants NovellusDx a patent for: METHODS FOR DETERMINING DRUG RESPONSE OF PATIENT SPECIFIC MUTATIONS

The EU Patent Office grants NovellusDx patent for: "METHODS FOR DETERMINING DRUG RESPONSE OF PATIENT SPECIFIC MUTATIONS". The patent, part of a large patent family, is fully owned by the company and protects its core technology. The post The EU Patent Office grants NovellusDx a patent for: METHODS F…

Michael Vidne, CCO, presents “Using Deep Learning to Predict Activity and Drug Response of Unknown Mutations” at NVIDIA’s GTC conference

NovellusDx was selected to present its Deep Learning machine learning framework to predict the activity and drug response of unknown mutations. The framework developed on Nvidia's GTX workstations harnesses the tremendous power of Graphical Processing Units (GPU) computing to accelerate the training…

NovellusDx and Primetech Sign an Exclusive Dealer Agreement in Japan

NovellusDx said today that it has signed a deal with Primetech for the distribution of its functional annotation for cancer treatment (FACT) assay in Japan. The post NovellusDx and Primetech Sign an Exclusive Dealer Agreement in Japan appeared first on NovellusDx.

The US Patent Office grants NovellusDx a patent for: METHODS AND SYSTEMS FOR IDENTIFYING PATIENT SPECIFIC DRIVER MUTATIONS

The US Patent Office grants NovellusDx patent for: "Methods and systems for identifying patient-specific driver mutations". The patent, the first of a large patent family, is fully owned by the company and protects its core technology. The post The US Patent Office grants NovellusDx a patent for: ME…
Show more

NovellusDx Company Life and Culture

Report incorrect company information

NovellusDx Frequently Asked Questions

  • When was NovellusDx founded?

    NovellusDx was founded in 2012.

  • Who are NovellusDx key executives?

    NovellusDx's key executives are Haim Gil-Ad, Michael Vidne and Gabi Tarcic.

  • Who are NovellusDx competitors?

    Competitors of NovellusDx include UNUM Therapeutics, Biotech Products Services and Research and Artios Pharma.

  • Where are NovellusDx offices?

    NovellusDx has an office in Jerusalem.

  • How many offices does NovellusDx have?

    NovellusDx has 1 office.